Welcome to our dedicated page for Eledon Pharmaceuticals news (Ticker: ELDN), a resource for investors and traders seeking the latest updates and insights on Eledon Pharmaceuticals stock.
Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN) is a clinical stage biotechnology company developing immune-modulating therapies centered on the CD40 Ligand (CD40L) pathway. The company’s news flow largely reflects progress with its lead investigational product, tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand that Eledon describes as having broad therapeutic potential.
News updates for ELDN commonly cover clinical trial milestones in kidney allograft transplantation, islet cell transplantation, xenotransplantation and amyotrophic lateral sclerosis (ALS). For example, Eledon has issued press releases on Phase 2 BESTOW trial results in de novo kidney transplant recipients, highlighting kidney function outcomes, safety and tolerability compared with tacrolimus-based regimens. Additional announcements have detailed updated data from a Phase 1b open-label kidney transplant study and long-term extension work.
Another recurring theme in Eledon’s news is the use of tegoprubart in islet transplantation for individuals with type 1 diabetes. The company has reported preliminary results from an investigator-initiated trial at the University of Chicago Medicine’s Transplant Institute, describing insulin independence and improved glycemic control in the first treated subjects. Eledon also issues updates on tegoprubart’s role in xenotransplantation, including its use as a key component of immunosuppression regimens in pig-to-human kidney transplant procedures at Massachusetts General Hospital.
Investors following ELDN news can also expect announcements related to scientific conference presentations, participation in healthcare conferences, financing transactions such as underwritten public offerings of common stock and pre-funded warrants, and selected financial results. This news page aggregates such disclosures so readers can review Eledon’s reported clinical data, corporate developments and regulatory-related communications over time.
Eledon Pharmaceuticals (Nasdaq: ELDN) reported Q3 2025 results and business highlights on Nov 14, 2025. Key points: Phase 2 BESTOW data showed tegoprubart with a favorable safety profile and an eGFR of approximately 69 mL/min/1.73m2 at 12 months in the treatment arm (n=51), supporting plans to advance to Phase 3 after regulator discussions. The company completed an underwritten public offering on Nov 13, 2025, raising $57.5 million gross (net ≈ $53.6M) to fund transplantation programs. Cash and short-term investments were $93.4 million as of Sept 30, 2025. Anticipated 2026 milestones include FDA guidance and initiation of a Phase 3 kidney transplant trial.
Eledon Pharmaceuticals (NASDAQ: ELDN) priced an underwritten public offering on Nov 12, 2025 to raise approximately $50 million gross. The offering includes 15,152,485 shares of common stock at $1.65 per share and, in lieu of common stock to certain investors, 15,151,515 pre-funded warrants at $1.649 each; the pre-funded warrants are immediately exercisable at $0.001 per share. Eledon granted underwriters a 30-day option to purchase up to 4,545,600 additional shares. The offering is expected to close on or about Nov 13, 2025, with net proceeds intended to support clinical development and general corporate purposes.
Eledon Pharmaceuticals (NASDAQ: ELDN) announced an underwritten public offering of shares of common stock and, for certain investors, pre-funded warrants to purchase common stock.
The company will grant underwriters a 30-day option to buy up to 15% additional shares (overallotment). The offering is subject to market and other conditions and may not be completed. Leerink Partners and Cantor are joint book-running managers.
Eledon intends to use net proceeds to support continued clinical development of product candidates, advance pipeline programs, and for general corporate purposes. The offering is made under a Form S-3 registration (File No. 333-282260) declared effective October 2, 2024, with a preliminary prospectus supplement to be filed with the SEC.
Eledon (NASDAQ: ELDN) reported Phase 2 BESTOW results for tegoprubart in kidney transplantation presented at ASN Kidney Week on November 6, 2025.
In a 127-patient randomized trial (tegoprubart n=63, tacrolimus n=64) tegoprubart produced a 12-month mean eGFR ≈69 mL/min/1.73 m² vs 66 mL/min/1.73 m² for tacrolimus, showed non-inferiority on the FDA composite efficacy-failure endpoint (22% vs 17% using a 20% margin), and demonstrated substantially lower rates of new-onset diabetes, tremor, delayed graft function and some cardiovascular events. Cash was ~$93.4M at 9/30/2025, funding operations into late 2026.
Eledon Pharmaceuticals (Nasdaq: ELDN) will present at the Guggenheim Second Annual Healthcare Innovation Conference on Wednesday, November 12, 2025 at 10:30 a.m. ET (7:30 a.m. PT). David-Alexandre C. Gros, M.D., CEO, will deliver the presentation. A live webcast will be available with a replay posted on the company website under Events for registered users.
Eledon Pharmaceuticals (Nasdaq: ELDN) announced an oral presentation of topline results from the Phase 2 BESTOW trial of tegoprubart for prevention of rejection in kidney transplantation at ASN Kidney Week 2025 in Houston on November 6, 2025.
The presentation by Andrew Adams, M.D., Ph.D. is scheduled for 5:30–5:42 p.m. CT in Grand Ballroom C. A conference call to discuss the results will be held on November 7, 2025 at 8:00 a.m. ET with a live webcast on the company investor site; the webcast will be archived after the call.
Eledon Pharmaceuticals (Nasdaq: ELDN) announced that its President and Chief Scientific Officer, Steve Perrin, Ph.D., will present at the 18th Congress of the International Xenotransplantation Association (IXA) in Geneva, Switzerland. The presentation will take place on October 1, 2025, from 10:30 a.m. to 12:00 p.m. CET during a plenary session focused on immunosuppression and anti-CD154 pathway blockade.
Eledon Pharmaceuticals (NASDAQ:ELDN) announced its upcoming participation in the Cantor Global Healthcare Conference. The company's CEO, David-Alexandre C. Gros, M.D., will engage in a fireside chat on September 5, 2025, at 9:10 a.m. ET.
Investors can register in advance for the webcast, and a replay will be available on the company's website in the Events section after the live session.
Eledon Pharmaceuticals (NASDAQ: ELDN) reported Q2 2025 financial results and clinical progress for its lead drug tegoprubart. The company highlighted positive Phase 1b data in kidney transplant patients, showing a mean 12-month eGFR of approximately 68 mL/min/1.73 m2, significantly better than the historical standard of care (~53 mL/min/1.73 m2).
Key developments include successful treatment of six islet cell transplant recipients at UChicago Medicine, with the first three achieving insulin independence, and a third patient receiving tegoprubart in kidney xenotransplantation at MGH. The company reported $107.6 million in cash as of June 30, 2025, expected to fund operations through 2026, and anticipates Phase 2 BESTOW trial results in kidney transplantation by November 2025.
Eledon Pharmaceuticals (NASDAQ: ELDN) presented updated data from its ongoing Phase 1b trial of tegoprubart for kidney transplant rejection prevention. The trial showed promising results with patients maintaining an average 12-month eGFR of 68 mL/min/1.73 m², significantly higher than the historical standard of care average of 53 mL/min/1.73 m².
The study enrolled 32 patients, with preliminary iBox data suggesting tegoprubart may achieve over 96% predicted 5-year allograft survival rate. The drug demonstrated strong safety profile with no deaths, graft loss, drug-related tremor, or new-onset diabetes. While six rejection episodes occurred, all were successfully treated, with patients remaining on tegoprubart showing superior kidney function recovery compared to those who switched to standard care.
The company expects topline results from its Phase 2 BESTOW trial in November 2025.